VA
VRDN icon

VR Adviser’s Viridian Therapeutics VRDN Stock Holding History

VR Adviser’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.9M Hold
3,882,709
– – 2.83% 10
2025
Q4 		$121M Hold
3,882,709
– – 5.97% 3
2025
Q3 		$83.8M Hold
3,882,709
– – 4.72% 5
2025
Q2 		$54.3M Hold
3,882,709
– – 4.07% 7
2025
Q1 		$52.3M Hold
3,882,709
– – 4.45% 6
2024
Q4 		$74.4M Hold
3,882,709
– – 5.11% 5
2024
Q3 		$88.3M Buy
3,882,709
+38
+0% +$621 4.63% 4
2024
Q2 		$50.5M Hold
3,882,671
– – 3.22% 11
2024
Q1 		$68M Buy
3,882,671
+48
+0% +$931 3.23% 9
2023
Q4 		$84.6M Buy
3,882,623
+800,001
+26% +$12.6M 5.8% 4
2023
Q3 		$47.3M Hold
3,082,622
– – 4.98% 3
2023
Q2 		$73.3M Buy
3,082,622
+382,757
+14% +$9.82M 11.73% 1
2023
Q1 		$68.7M Hold
2,699,865
– – 13.41% 1
2022
Q4 		$78.9M Buy
2,699,865
+569,557
+27% +$13.1M 13.29% 1
2022
Q3 		$43.7M Buy
2,130,308
+277,389
+15% +$4.99M 6.74% 5
2022
Q2 		$21.4M Hold
1,852,919
– – 4.22% 9
2022
Q1 		$34.3M Hold
1,852,919
– – 5.55% 7
2021
Q4 		$36.6M Buy
1,852,919
+1,833,424
+9,405% +$34.2M 5.01% 7
2021
Q3 		$321K Hold
19,495
– – 0.04% 26
2021
Q2 		$357K Hold
19,495
– – 0.04% 29
2021
Q1 		$326K Hold
19,495
– – 0.04% 28
2020
Q4 		$321K Buy
+19,495
New +$294K 0.05% 25

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VR Adviser's VRDN Position: Q1 2026 in Review

VR Adviser held its Viridian Therapeutics (VRDN) position steady in Q1 2026 at 3,882,709 shares worth $75.9M. The position accounts for 2.83% of the portfolio, ranked #10.

VR Adviser first reported a position in VRDN in Q4 2020 and has held it in 22 quarters since. The position peaked at $121M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • VR Adviser held 3,882,709 shares of Viridian Therapeutics worth $75.9M as of Q1 2026.
  • VR Adviser left its Viridian Therapeutics share count unchanged in Q1 2026.
  • Viridian Therapeutics made up 2.83% of VR Adviser's portfolio in Q1 2026, its #10 holding.
  • VR Adviser first reported a position in Viridian Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • VR Adviser's Viridian Therapeutics position peaked at $121M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.